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Abstract: Coronary heart disease is a leading cause of mortality and morbidity. Those that sur-
vive acute myocardial infarction are at significant risk of subsequent heart failure due to fibrotic
remodelling of the infarcted myocardium. By applying knowledge from the study of embryonic
cardiovascular development, modern medicine offers hope for treatment of this condition through
regeneration of the myocardium by direct reprogramming of fibrotic scar tissue. Here, we will
review mechanisms of cell fate specification leading to the generation of cardiovascular cell types
in the embryo and use this as a framework in which to understand direct reprogramming. Driving
expression of a network of transcription factors, micro RNA or small molecule epigenetic modifiers
can reverse epigenetic silencing, reverting differentiated cells to a state of induced pluripotency. The
pluripotent state can be bypassed by direct reprogramming in which one differentiated cell type
can be transdifferentiated into another. Transdifferentiating cardiac fibroblasts to cardiomyocytes
requires a network of transcription factors similar to that observed in embryonic multipotent cardiac
progenitors. There is some flexibility in the composition of this network. These studies raise the
possibility that the failing heart could one day be regenerated by directly reprogramming cardiac
fibroblasts within post-infarct scar tissue.
Keywords: reprogramming; stem cell; regenerative medicine; induced pluripotent stem cell; myocar-
dial infarction; heart failure
1. Introduction
Myocardial infarction (MI; commonly known as a heart attack) is one of the leading
causes of mortality and morbidity in the Western world. MI is caused by occlusion
of a coronary artery leading to ischaemic myocardial cell death. Remodelling of the
myocardium following a myocardial infarction results in the formation of a fibrotic scar
leading to subsequent heart failure, and this is a significant cause of mortality amongst
survivors of myocardial infarction [1–3].
Recent advances in regenerative medicine have raised the possibility that this scar
tissue itself could be used as the basis for the restoration of function. We now understand
that cell fate is not irreversibly determined during embryonic development but that the
epigenetic mechanisms that maintain cell fate in a structure such as the heart can be reversed
using the tools of molecular biology. Fifteen years ago, it was demonstrated that a fully
determined somatic cell, such as a skin fibroblast, could be converted by driving expression
of four transcription factors into an induced pluripotent state resembling an embryonic
stem cell, from which any somatic cell type could subsequently be differentiated [4]. This
technology, in turn, subsequently led to efforts to directly convert one somatic cell type into
another in a process known as transdifferentiation [5–7]. These efforts offer the possibility
that in myocardial infarction patients, fibrotic scar tissue could one day be induced to
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transdifferentiate into functional myocardium, reversing heart failure and improving both
quality of life and survival rates.
In this review, we will describe the molecular mechanisms that specify the major car-
diac cell types in the embryo and use this as a framework to understand attempts to change
cell fate in regenerative medicine. Many transcription factors, as well as other regulators of
gene expression such as micro RNA, have been repurposed for therapeutic applications in
an attempt to convert the scar tissue that forms during remodelling following a myocardial
infarction into contractile tissue to restore the function of the heart. We will provide an
overview of the many methods used and comment on the current state of the field.
2. Embryonic Development of the Heart
2.1. Cellular Composition of the Adult Heart
Cardiomyocytes, the force-producing contractile muscle of the heart, make up about
70–85% of the volume of the heart but only around a third of the total cell number [8].
The adult human heart contains as many as nine major cell types and 20 sub-types [8].
Cardiomyocytes are characterised by expression of contractile filaments within the sarcom-
ere comprising proteins such as myosin heavy chain (MYH7, MYH6), cardiac alpha actin
(ACTC1), alpha actinin (ACTN1), myomesin (MYOM1, MYOM2), titin (TTN), and troponin
(TNNT2, TNNI3, TNNC1). The regulation of these genes is complex, and many exhibit
isoform-specific changes during cardiomyocyte maturation [9–11]. Cardiomyocytes within
the adult heart are not a homogenous population. There are, for example, differences
between ventricular and atrial cardiomyocytes, while specialised cardiomyocytes form the
conduction system.
Non-cardiomyocytes make up the majority of cells within the heart. These are essential
for its function, providing structure through secretion of the extracellular matrix, providing
the vascular supply and mediating homeostasis. Recent advances in single-cell RNA
sequencing have allowed us to map the diversity of cell types within the heart based on
transcriptional profiling and to follow changes during embryonic development and in
disease [12,13]. Estimates of the precise proportions of each cell type vary, and there may
be species differences [14].
Cardiac fibroblasts provide structural support through secretion of type I fibrillar col-
lagen, forming a matrix in which is embedded the cardiomyocytes [15]. Cardiac fibroblasts
also have a remarkable ability to sense and respond to stress or injury (discussed below).
Fibroblasts are a molecularly heterogeneous population of cells with a gene expression
profile overlapping multiple cell types16. Indeed, a lack of specific markers has impaired
their study [16]. Genes expressed by fibroblasts include THY1/CD90, the intermediate
filament vimentin and various collagens. Surprisingly, cardiac fibroblasts also express
many transcription factors shared with cardiogenic precursors, including GATA4, NKX2.5,
and MEF2C [17].
Other non-cardiomyocyte cell types include those comprising the vascular system of
the heart (endothelium, pericytes, and vascular smooth muscle) and the immune system,
including all types of leukocytes, as well as a large population of resident macrophages [18].
2.2. Fate Specification and Lineage Restriction during Embryonic Heart Development
During embryogenesis, the developmental potential (potency) of a cell is gradually
restricted as it becomes committed to a specific lineage. The embryo is derived from pluripo-
tent stem cells residing within the inner cell mass of the blastocyst. These cells contain
open chromatin in an unmethylated state. As development proceeds, alternative cell fates
are permanently closed through DNA methylation [19] and chromatin remodelling [20], re-
sulting in the production of heterochromatin. Cell fate is largely regulated by transcription
factors that recruit epigenetic modifiers such as chromatin remodelling complexes.
One of the earliest events in embryonic development is the lineage restriction event
producing the three primary germ layers: the endoderm, mesoderm, and ectoderm. Most
cardiovascular cell types are derived from the mesoderm germ layer. Within the mesoderm
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lineage, the next fate restriction divides this population into paraxial, intermediate, and
lateral plate mesoderm; the lateral plate mesoderm is then physically divided by formation
of the coelom into splanchnic (or visceral) and somatic mesoderm [21].
Cardiomyocytes have a single embryonic origin, being derived from a region of the
splanchnic mesoderm known as the pre-cardiac mesoderm (Figure 1a). The transcription
factor MESP1 is the earliest marker of multipotent cardiac progenitors and is expressed in
some cells as they migrate from the primitive streak [22]. The precise function of MESP1
is unclear [23–26], but there is no master regulator of the cardiomyocyte lineage akin to
MYOD in skeletal muscle and MESP1 alone is insufficient to specify cardiac progenitors [27].
Specification appears, instead, to depend not on a single transcription factor, but on a
network of interacting factors activated downstream from MESP1 [28–31]. MESP1+ cells
give rise at different timepoints to two distinct progenitor populations, the first and second
heart fields [32], which may be distinguished on the basis of a distinct but overlapping
expression profile (Figure 1b). The transcription factors NKX2.5 [33] and GATA4 [34] are
common to both populations, while the primary field additionally expresses TBX5 [35] and
the secondary field expresses MEF2C [36] and ISL1 [37]. However, it should be noted that
each of these factors is expressed in a broader domain and it appears to be the combination
of factors that determine fate. For example, ISL1 is also expressed earlier in development in
a proliferating cardiac progenitor population that gives rise to both first and second heart
field lineages [38], while MEF2C is widely expressed in the embryo, its second heart field
expression being driven by a specific cardiac enhancer [39].
It appears that one of the key events in cardiomyocyte specification is the repression
of alternative muscle cell fates. The three contractile muscle types (cardiac, skeletal, and
smooth) share many properties but commonly express different isoforms of related genes
(e.g., myosins). Myocardin (MYOCD) is a transcriptional co-activator of the ubiquitously
expressed transcription factor serum response factor (SRF) [40]. It is expressed in cardiac
progenitors and in vascular smooth muscle. MYOCD is negatively regulated by the micro
RNAs miR1 and miR133a, which are expressed in cardiac and skeletal muscle. High levels
of MYOCD drive specification of smooth muscle in preference to cardiomyocytes [41].
Unlike cardiomyocytes, both cardiac fibroblasts and vascular smooth muscle may be
derived from multiple lineages, which converge on a common cell fate (Figure 1a). Perhaps
for this reason, both cell types are highly plastic and show an ability to transdifferentiate to
a migratory state under certain conditions. Cardiac fibroblasts are a poorly defined popula-
tion of cells of multiple embryonic origins [42]. About 80% of cardiac fibroblasts residing
within the myocardium are derived from the outer layer of the heart, the epicardium, while
the rest are largely derived from the endocardium [43,44], specifically from valve endothe-
lium. The epicardium is derived from the intermediate mesoderm lineage and appears
to share a common origin and gene expression profile to the kidney [45], for example in
expression of the Wilm’s tumour transcription factor WT1. Multipotent progenitor cells
known as epicardium-derived cells (EPDCs) migrate into the heart in mid gestation where
they differentiate into multiple cell types including fibroblasts, endothelium, and smooth
muscle [45]. In contrast, the endothelium is derived from the lateral plate mesoderm and
shares a common origin with haematopoietic lineages, both being derived from a common
precursor, the haemangioblast [46,47].
A minority of cardiac cells arise from an extra-mesodermal origin. The ectoderm
lineage forms the neural crest, a population of multipotent progenitor cells that arises on
the edge of the neural plate and migrate to various parts of the body. The cardiac neural
crest migrates into the forming heart tube to populate the outflow tract and contributes to
smooth muscle and vascular endothelium [48].
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muscle, endothelium and cardiac fibroblasts (via the endocardium). Most cardiac fibroblasts, however,
are derived from the epicardium, which can also generate smooth muscle. The neural crest, of
ectodermal origin, contributes some smooth muscle as well as other cell types not shown in the
diagram (valve interstitial cells, neurons and great artery fibroblasts). (b) Simplified version of the
cardiogenic network that specifies cardiogenic progenitors. GATA4 and NKX2-5 are expressed in all
progenitors, while other factors are expressed only in the first or second heart fields.
3. Cellular Events Resulting from Myocardial Infarction
3.1. Initial Inflammatory Response
Occlusion of a coronary artery leads to ischaemic myocardial cell death. Death occurs
by both necrosis and apoptosis and is observed both within the infarct itself and within the
surrounding region. Cell death peaks within the first 24 h after infarction, although low
levels of cell death persist for several months as cardiac remodelling progresses [49].
An inflammatory response leads to activation of the innate immune system within
minutes of an infarction. Necrotic cardiomyocytes themselves release a number of sig-
nals into the circulation collectively known as damage-associated molecular patterns
(DAMPs) [18]. Inflammatory cytokines are also produced by a range of resident cells
including macrophages, mast cells, fibroblasts and surviving cardiomyocytes. For example,
cardiomyocytes produce interleukin-6 [50], while macrophages produce CXCL8 [51]. These
signals serve to recruit circulating neutrophils and monocytes into the heart, where they
differentiate into macrophages and phagocytose necrotic cells.
After several days, inflammation is reduced, neutrophil numbers drop, and the injured
heart enters a reparative phase, mediated by macrophages [18]. Macrophages release VEGF
to promote angiogenesis and TGFβ, which has many functions but crucially activates and
recruits fibroblasts into the heart [52]. Thus, this is a temporary phase, but initiates the start
of fibrosis, leading to permanent changes in the heart.
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3.2. Fibrosis
Primitive vertebrates such as the zebrafish [53,54], together with neonatal mam-
mals [55], are able to regenerate the heart following injury. In these cases, little or only
transient scarring is observed prior to regeneration, and a dampened immune response
is seen. In contrast, the adult mammalian heart is unable to regenerate and therefore a
damage limitation strategy is employed, which involves the process of fibrosis. Fibrosis is
the replacement of dead contractile tissue with live connective tissue, fibroblasts, in order to
maintain structural integrity. This repair, which is initially beneficial, becomes pathogenic
when it results in uncontrolled deposition of ECM protein and scar tissue formation [56].
Cardiac fibroblasts are much less sensitive to ischaemia than cardiomyocytes and
generally survive an infarction. In addition to endogenous cardiac fibroblasts, fibroblasts
of multiple origins are recruited into the heart upon injury. This includes lineages that
do not contribute cardiac fibroblasts during embryogenesis, such as haematopoietic bone
marrow-derived cells [57,58].
Fibroblasts have a remarkable ability to undergo transdifferentiation. TGFβ signalling
serves not only to recruit fibroblasts into the heart, but also acts to phenotypically transform
them to become myofibroblasts [59]. These are cells that combine features of a fibroblast
and a smooth muscle cell; they are able to secrete large amounts of extracellular matrix
proteins such as collagen, but also have contractile ability through the expression of α-
smooth muscle actin (ACTA2) microfilaments [60,61]. Myofibroblasts are normally absent
in healthy myocardium, but become highly abundant shortly after injury [60]. Although
it was previously thought that these cells are derived from the migratory fibroblasts
recruited into the heart upon injury, it is now thought that the majority of activated
myofibroblasts are derived from transdifferentiated resident cardiac fibroblasts from the
epicardial lineage [16]. Transdifferentiation of fibroblasts is generally regarded as a two-
step process. Fibroblasts initially differentiate into a highly proliferative form known
as an activated fibroblast [16]. These cells contribute to the innate immune response
removing damaged tissue through both the recruitment of monocytes (by secretion of
inflammatory cytokines and chemokines), and secretion of matrix metalloproteinases,
which act to degrade the extracellular matrix, releasing damaged or dead cardiomyocytes
for phagocytic clearance [62]. While it was previously believed that scar tissue collagen
is deposited only by activated myofibroblasts, recent genomics analysis performed in the
mouse suggests that macrophages also directly contribute collagen [63].
3.3. Progression to Heart Failure
Heart failure is a progressive loss of efficiency of the heart. Structural and functional
remodelling of the heart as a response to stress and can be seen, for example, in response
to exercise. However, pathological remodelling is a response to disease and results in
deposition of extracellular matrix coupled with cardiomyocyte necrosis [64]. Although
scar formation is initially beneficial to the heart, persistent myofibroblasts lead to an
accumulation of fibrous tissue [15]. This, in turn, leads to progressive adverse myocardial
remodelling [15]. Heart failure due to pathological fibrotic remodelling is a major cause
of mortality in survivors of myocardial infarctions [65,66], and this is the reason why
regeneration of the myocardium and reversal of fibrosis is so important.
4. Regenerative Medicine
Regenerative medicine holds much promise for repair of the injured heart. Repro-
gramming through forced expression of transcription factors has been shown to reverse
epigenetic silencing of the genome leading to a state of induced pluripotency (Section 4.1).
The same technology has been adapted to directly reprogramme somatic cells from one
fate to another, bypassing the pluripotent state (Section 4.2). Such approaches raise the
possibility that cardiac fibroblasts within post-infarct scar tissue could be converted into
cardiomyocytes to reverse pathological remodelling. In this section, we will first describe
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the principles of induced pluripotency before going on to discuss direct reprogramming in
the heart.
4.1. Induced Pluripotent Technology
Pluripotency in the embryo is determined and maintained, not by a single transcription
factor, but by a network of transcription factors that includes at its core OCT4, SOX2, and
NANOG [67]. The network appears to operate by synergistic mutual activation of members
of the core network together with repression of genes promoting differentiation. The three
core factors cooperatively bind to regulatory elements of target genes [67]. Multiple levels
of pluripotency exist spanning the range from naïve to primed pluripotency [68], this latter
state being that of the post-implantation epiblast.
As development proceeds, these cells lose potency to become firstly multipotent
stem cells such as the cardiac progenitors described above and ultimately to become fully
differentiated cells. Fate specification was for a long time considered to be an irreversible
process, as described in Waddington’s famous analogy of a ball rolling downhill through an
epigenetic landscape of bifurcating valleys [69]. This notion was overturned in 2006 when
it was shown that a differentiated cell type (mouse fibroblasts) could be “reprogrammed”
back to a pluripotent state [4]. Takahashi and Yamanaka screened a panel of 24 candidate
genes (selected either for their expression in embryonic stem cells or oncogenic properties)
for their ability to reprogramme. Retroviral expression of all 24 factors successfully induced
pluripotency as demonstrated by upregulation of an Fbx15 reporter gene. By progressively
eliminating factors, Takahashi and Yamanaka were able to identify a minimum network of
just four factors required for reprogramming, which have become known as the Yamanaka
or OKSM factors: the ESC transcription factors OCT3/4 and SOX2, and the oncogenes
cMYC and KLF4. These same factors were subsequently shown to reprogramme human
dermal fibroblasts to a pluripotent state [70].
Thus, as is the case for embryonic cardiogenic specification, there is no single factor
determining pluripotency, but rather a network of synergistic interacting factors performs
this function. The precise makeup of the network appears to be somewhat flexible, as
demonstrated by the observation that the oncogenes MYC and KLF4 can be substituted
for NANOG and LIN28A [71]. The requirement for LIN28A is particularly interesting
because this gene is not a transcription factor, but rather has a post-transcriptional function.
LIN28A is an RNA-binding protein that can regulate both the processing of micro RNA
(mIR) from precursors and the translation of coding mRNAs [72].
A number of groups have improved upon the original reprogramming methods,
particularly in order to improve safety and translational clinical potential by reducing
the potential for tumour formation. Methods include the use of non-integrating episomal
plasmids derived from the Epstein-Barr virus [73,74], the use of mRNA [75], or the use of
small molecules [76].
4.2. Direct Reprogramming of Cardiac Fibroblasts
The work of Yamanaka’s group and others opened the door to personalised medicine.
It was now possible, in theory at least, to take a skin biopsy from a patient and use this
to generate an induced pluripotent stem cell (iPSC), which could then be differentiated
in vitro into cardiovascular cell types using growth factors present in the embryo such as
Nodal/Activin, FGF2 and BMP4 [77] (Figure 2). Such differentiated cells can be seeded onto
a decellularised scaffold to generate a patch of tissue that may grafted during surgery. This
has proven useful in the repair of some congenital heart diseases such as ventricular septal
defect or valve replacement [78]. Many groups are also investigating the use of such patches
to repair myocardial infarction. For example, Wang et al. seeded human iPSC-derived
cardiomyocytes and fibroblasts onto a decellularised matrix and demonstrated that this
patch reduced infarct size and improved cardiac function in a rat model of MI [79]. Su et al.
used a microfluidics approach to engineer a network of blood vessels made from human
umbilical cord endothelial cells, before seeding this with iPSC-derived cardiomyocytes [80].
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An alternative approach, and the subject of this review, is that cardiac fibroblasts residing
within the scar tissue itself might be reprogrammed in vivo to achieve regeneration of the
injured myocardium.
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different ch omatin remodelling. Heterochromatic regions of the genome specifying the
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the gene regulato y netw k comprising MYOCD, miR1, and miR133a, appears to cont ol
the selection of one f the muscle fates (cardiac, smooth or skeletal) through repression of
alternative cell fates [41] (discussed above).
Fibroblasts are rtic l rl attractive targets for direct reprogramming efforts because
they are a naturally plastic cell type with the ability to transdifferentiate under certain
conditions (Section 3.2). Cardiac fibroblasts, in addition, share considerable gene expres-
sion with cardiac progenitors, including many transcription factors of the cardiogenic
network [17].
4.3. Identification of a Cardiogenic Network in Mouse Models
Ieda et al. [81] from Deepak Srivistava’a lab used a strategy similar to that previously
used by Takahashi and Yamanaka by generating a transgenic reporter mouse that could be
used to monitor fate specification. Ieda et al. chose to use MYH6 (α myosin heavy chain) as
a marker of mature cardiomyocytes. The reader will recall that the regulation of the myosin
heavy chain genes is complex. This family of genes demonstrates species and muscle type
differences, in addition to being subject to developmental isoform switching [11,82]. In
the human heart MYH6 is largely restricted to the atria while MYH7 is expressed in the
ventricles, although there is some co-expression during embryonic development [83]. In
mice, both MYH6 and MYH7 are co-expressed in the early heart tube, in later embryos
the atrial/ventricular dichotomy seen in the human heart is transiently observed, before
MYH6 becomes the dominant pan-cardiomyocyte marker in the postnatal heart [84]. Thus,
it is not entirely correct that MYH6 expression is a reporter of the mature cardiomyocyte
cell fate in mice as it is expressed as early as embryonic day 7.5 [84]. Nevertheless, this
reporter has been subsequently used in many rodent studies (Tables 1 and 2).
Ieda et al. [81] screened a pool of 14 transcription factors known to be expressed in
cardiac progenitors for their ability to transdifferentiate fibroblasts. Ieda et al. gradually
removed factors from this pool to identify the minimum combination sufficient for re-
programming. This work confirmed that MESP1 is insufficient for reprogramming, and
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indeed MESP1 is not present within the identified combination. Instead, they found that
three factors GATA4, MEF2C, TBX5 (herein referred to as GMT) are: required. Thus, as in
embryonic development, the cardiac lineage is not specified by a single factor, but by a
synergistic network of cardiogenic factors. One interesting feature of this network is that
it includes factors expressed largely in the first heart field (TBX5) and the second heart
field (MEF2C) as well as one shared factor (GATA4). TBX5 has, however, been shown
to be expressed in the posterior second heart field [85], where co-expression of all three
factors occurs.
MEF2C and TBX5 have been shown to have properties of pioneer transcription factors,
binding to regions of heterochromatin and facilitating chromatin remodelling to reactivate
previously closed regions of the genome [86]. At the same time, enhancers active in fibrob-
lasts are silenced [87]. MEF2C in particular appears to be a key element with MEF2 binding
sites in the genome acting as sites of recruitment for multiple transcription factors [87]. In
addition, the use of polycistronic expression constructs, which drive higher expression of
MEF2C over GATA4 and TBX5, seem to be more efficient at reprogramming [88].
Another feature of the network is the importance of a combinatorial code for a specific
cell fate [86,87]. Each transcription factor of the network is expressed in multiple cell types
during development and therefore it is the specific combination of factors bound at a given
locus that result in a specific outcome. Synergistic binding of transcription factors to target
genes has been demonstrated, for example, in MEF2C and TBX5 to the target MYH6 [89].
As was found to be the case for the pluripotent network, the cardiogenic network
exhibits flexibility, and a number of groups have subsequently demonstrated that a number
of different combinations of factors achieve similar results. It would be impossible to dis-
cuss each of these in detail in a single review, but we have summarised the strategies used
by these groups in Table 1. Table 2 summarises the results of these experiments. Most repro-
gramming combinations have at their core the GMT factors identified by Ieda. The Olson
lab discovered that addition of a fourth transcription factor, HAND2, to the reprogramming
cocktail improved efficiency [90] and the resulting GMHT cocktail has subsequently been
used with various modifications in subsequent studies by the Olson [91–93], Song [94], and
Gearhart [95,96] labs. Protze et al. tested 120 different three factor combinations and found
that many different triplets elicited some degree of reprogramming [97]. Seven factors
were most commonly seen in these networks: GATA4, MEF2C, TBX5, MESP1, NKX2.5, and
MYOCD [97].
Repression of the fibroblast cell fate through inhibition of either TGFβ or RhoA/ROCK
signalling has been found to enhance the effectiveness of the cardiogenic network [92].
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Transcription Factors miRNA Pathway Targeting




Mouse X X X Ieda 2010 [81]
Mouse X X X Qian 2102 [98]
Human X X X X X X X Fu 2013 [99]
Mouse X X X I I Mohamed 2017 [100]
Olson
Mouse X X X X Song 2012 [90]
Human X X X X X X Nam 2013 [101]
Mouse X X X X A Zhou 2015 [92]
Mouse X X X X X A Zhou 2017 [93]
Mouse X X X X I Abad 2017 [91]
Ieda
Mouse X X X Inagawa 2012 [102]
Human X X X X X Wada 2013 [103]
Mouse X X X X
Muraoka 2014 [104]
Human X X X X X
Mouse X X X A A Yamakawa 2015 [105]
Dzau Mouse X X X X I Jayawardena 2012 [106]
Gearhart
Mouse X X X X X Addis 2013 [95]
Mouse X X X X X I Ifkovits 2014 [96]
Song Mouse X X X X X X I I Zhao 2015 [94]
Ravens Mouse X X X Protze 2012 [97]
Qian
Mouse X X X Wang 2015 [88]
Mouse X X X X Wang 2020 [5]
Human X X X X Garbutt 2020 [107], Zhou2019 [108]
Xie Mouse A I A A Fu 2015 [109]
Kamp Mouse X X X X A Lalit 2016 [110]
Leong Human X X X X X X X Christoforou 2017 [111]
Wu Mouse X X X Chen 2012 [112]
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Table 2. Reprogramming efficiencies of methods used to reprogramme cells into cardiomyocytes. Refer to Table 1 for details of reprogramming strategy used. MEF = mouse
embryonic fibroblast.
Laboratory Species In vitro/In Vivo Source Cell Developmental Stage Reprogramming Efficiency Comments Reference
Srivistava
Mouse In vitro Cardiac Fibroblast Postnatal 20% express MYH6 at 10 days
Although transdifferentiation is
rapid, maturation (gain of TNNT2)
takes several weeks
Ieda 2010 [81]




Report that GMT alone cannot








Cardiac fibroblast Adult 6.8% express both MYH6 andTNNT2 Efficiency is 1.4% with GMT alone
Song 2012 [90]Tail tip Fibroblast Adult
9.2% express both MYH6 and
TNNT2
In vivo Cardiac Fibroblast Adult At least 10,000 cellstransdifferentiated
Improves heart function following
infarction
Human In vitro
Cardiac Fibroblast Adult 13% express TNNT2 Sarcomere structures and calcium
transients seen at 4–11 weeks
Nam 2013 [101]
Dermal fibroblast Adult 9.5% express TNNT2
Mouse In vitro
MEF Embryo ~25% express both MYH6 andTNNT2
Reprogramming more efficient in
embryonic than adult cells. Zhou 2015 [92]Tail tip fibroblast Adult
~5% express both MYH6 and
TNNT2
Cardiac Fibroblast Adult ~6% express both MYH6 andTNNT2
Mouse In vitro Tail tip fibroblast Adult ~28% express both MYH6 andTNNT2 after 7 days
Suppresses inflammatory
signalling Zhou 2017 [93]
Mouse In vitro MEF Embryo Up to 70% express MYH6 andTNNT2 or ACTN2
Improves efficiency of generation
of mature cardiomyocytes by
GMHT by 5–6 fold
Abad 2017 [91]
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Table 2. Cont.
Laboratory Species In vitro/In Vivo Source Cell Developmental Stage Reprogramming Efficiency Comments Reference
Ieda
Mouse In vivo Cardiac Fibroblast Adult 3% express MYH6 at 1 week
Reprogramming efficiency is
lower than in other mouse in vivo
studies
Inagawa 2012 [102]
Human In vitro Cardiac Fibroblast Adult 5% express TNNT2 and ACTN2 at4 weeks
Report that GMT alone cannot
reprogramme human cells. Wada 2013 [103]
Mouse In vitro MEF Embryo ~35% express MYH6 at 1 week Cardiomyocytes mature morequickly than GMT alone Muraoka 2014 [104]
Human In vitro Cardiac Fibroblast Adult ~20% express TNNT2 at 1 week
Mouse In vitro MEF Embryo ~70% beating cells at 4 weeks Yamakawa 2015 [105]
Dzau
Mouse In vitro Fibroblast
1.5–7.7% express MYH6 with miR






Mouse In vivo Cardiac Fibroblast Adult Induced cardiomyocytes represent~1% of total and express TNNT2
Gearhart
Mouse In vitro MEF Embryo ~1.5% show calcium oscillations at2 weeks
Developed a quantifiable calcium
reporter to assay efficiency
HNGMT reported to be >50-fold
more efficient than GMT alone
Addis 2013 [95]
Mouse In vitro MEF Embryo ~15% show calcium oscillations at2 weeks
TGFβ inhibition improves
efficiency 5 fold over HNGMT
alone
Ifkovits 2014 [96]
Song Mouse In vitro
MEF Embryo Zhao 2015 [94]
Cardiac Fibroblast Adult
Up to 18% express TNNT2 at 4
weeks.
2.5% beating at 5 weeks
Tail tip fibroblast Adult
Up to 20% express TNNT2 at 4
weeks.
4% beating at 5 weeks
Ravens Mouse In vitro MEF Embryo 2.5% express MYH6 Found that a number of tripletcombinations can be used. Protze 2012 [97]
J. Cardiovasc. Dev. Dis. 2021, 8, 72 12 of 21
Table 2. Cont.
Laboratory Species In vitro/In Vivo Source Cell Developmental Stage Reprogramming Efficiency Comments Reference
Qian
Mouse In vitro Cardiac Fibroblast Adult ~10% express MYH6, ~5% expressTNNT2
Demonstrated that expression of




In vitro MEF Embryo ~10% express TNNT2 (GMT)
Use of Sendai virus improves
efficiency over retrovirus Miyamoto 2018 [113]
In vitro Tail tip fibroblast Postnatal ~22% express TNNT2 (GMHT)
In vivo Cardiac Fibroblast Adult ~1.5% express TNNT2 (GMT)
Human In vitro Cardiac Fibroblast Adult
~4% express TNNT2 (GMTMM)
~15% express TNNT2
(GMTMM+miR133)
Mouse In vitro(In vivo) Cardiac Fibroblast Adult
Becn1 shRNA knockdown
improves GMT efficiency Wang 2020 [114]
Human In vitro H9 ES-derivedfibroblast n/a 40–60% express TNNT2 at 2 weeks Very efficient streamlined cocktail
for human cells
Garbutt 2020 [107]
Human In vitro Cardiac Fibroblast Adult ~40% express TNNT2 at 2 weeks Zhou 2019 [108]
Xie Mouse
In vitro MEF Embryo 14.5% express ACTN2, 9% MYH6
on day 24 Fu 2015 [109]In vitro Tail tip fibroblast Adult
Kamp Mouse





Lalit 2016 [110]In vitro Lung fibroblast Adult
In vitro Tail tip fibroblast Adult
Leong Human In vitro Dermal fibroblast Adult Not stated Christoforou 2017[111]
Wu Mouse
In vitro Cardiac Fibroblast 2–3 weeks No MYH6 expression at 3 weeks
Data suggest GMT
reprogramming is inefficient Chen 2012 [112]In vitro Tail tip fibroblast Adult No MYH6 expression but 35%express TNNT2 at 3 weeks
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4.4. Reprogramming Human Cells
Human cells have proven to be more refractory to reprogramming than mouse cells,
and not all findings in the rodent model have been found to be directly applicable to
man. In particular, the GMT combination, which works well in mice, has been found to
be insufficient to reprogramme human fibroblasts [99,103]. This impasse was overcome
in 2013 when three different labs published three different methods for reprogramming
human cells. The Srivistava lab used a reprogramming network of seven transcription
factors (GATA4, MEF2C, TBX5, MESP1, MYOCD, ESRRG, and ZFPM2) [99], the Olson
lab used a network of four transcription factors (GATA4, TBX5, MYOCD, and HAND2)
together with two micro RNAs (miR-1 and miR-133a) [101], whilst Ieda’s lab used a five
factor network (GATA4, MEF2C, TBX5, MESP1, and MYOCD) [103]. Direct comparisons
between the methods are difficult because each group used a slightly different method to
assay reprogramming efficiency (Table 2).
4.5. In Vivo Reprogramming of the Injured Heart
Whereas most studies to date have been performed in vitro, the attraction of this
technology is that it raises the possibility to reprogramme the injured heart in vivo, thus
repairing the myocardium at the same time as reducing pathological remodelling. Re-
programming in vivo presents a new set of challenges, such as that of delivering the
reprogramming factors to the correct cells and a much more variable cellular environment
in which to induce such changes.
Four ground-breaking studies were published by different labs in close succession in
2012 (Tables 1 and 2).
Qian et al. [98], working in Srivastava’s lab, and Inagawa et al. [102], working on
Ieda’s lab, independently demonstrated in vivo reprogramming of murine cardiac fibrob-
lasts by retroviral delivery of GMT following myocardial infarction induced by coronary
artery ligation. Qian et al. found that the retrovirus delivered to the myocardium border-
ing the infarct zone on the same day as infarction can transduce proliferating vimentin
positive activated fibroblasts in the injured heart, but not non-proliferating cells such as
resident cardiac fibroblasts in the normal heart. Whilst this could be seen as a limitation on
the efficiency of reprogramming, it is advantageous to be able to target reprogramming
specifically to the cells participating in remodelling, reducing off-target effects. Lineage
tracing using periostin CRE revealed that ACTN1 positive induced cardiomyocytes were
indeed derived from fibroblasts. Qian et al. found that although reprogramming efficiency
(10–15%) was similar to that observed in vitro, the induced cardiomyocytes produced
were more mature in vivo and they had sarcomeric structures resembling endogenous
cardiomyocytes. Statistically significant improvements in cardiac function were seen by
8–12 weeks in reprogrammed hearts relative to controls including in the ejection fraction,
stroke volume and cardiac output.
Inagawa et al. [102] also transduced GMT using a retroviral vector immediately
following coronary artery ligation. An MYH6 reporter was expressed in 3% of viral
infected cells after 2 weeks, a rate much lower than observed by Qian et al., and again
only proliferating cells were targeted. Improvements in cardiac physiology were not
investigated in this study.
Song et al. [90], working in Olson’s lab, used a similar strategy to test in vivo repro-
gramming by injecting GMHT retrovirus immediately following coronary artery ligation.
Lineage tracing using a different CRE line, the fibroblast-specific calcium-binding protein
S100A4, confirmed transdifferentiation of proliferating fibroblasts. Assessment of cardiac
physiology demonstrated a progressive reduction in fractional shortening and ejection
fraction beginning 24 h after injury in controls. This loss of efficiency was reduced in GMHT
hearts in the weeks following injury. By 12 weeks post-injury, stroke volume of GMHT
treated animals exceeded that of unoperated controls, while ejection fraction approached
this level. Thus, these animals showed a greater improvement in function than GMT
treated animals. Fibrosis was also reduced.
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Jayawardena et al. [106], working in Dzau’s lab, used a lentivirus to deliver four micro
RNAs to the injured heart and were also able to demonstrate transdifferentiation of S100A4
CRE cells. This method did not improve cardiac function immediately after ligation but
was shown to significantly improve fractional shortening and velocity of circumferential
fibre shortening by 2–3 months after injury [115].
The above studies utilise viral vectors that raise safety concerns regarding insertional
mutagenesis, limiting their clinical applications. In 2015, Miyamoto et al. [113], working
in Ieda’s lab, tested the use of a non-integrating Sendai virus vector. This virus replicates
in the cytoplasm and does not integrate into the host genome, expression of reprogram-
ming factors is therefore transient and not inherited by daughter cells upon cell division.
Surprisingly, Miyamoto et al. found that this vector improved both efficiency of reprogram-
ming and maturation of the resulting cells when reprogramming using GMT. In addition,
immunostaining revealed specific targeting of cardiac fibroblasts and not cardiomyoctes.
Functional studies demonstrated significant improvements in ejection fraction and func-
tional shortening relative to controls at 4 weeks as well as a significant reduction in fibrotic
area. An alternative approach was taken by Chang et al., working in Kim’s lab, who used
gold nanoparticles coated with an arginine-rich peptide in order to deliver GMT to the
mouse heart following coronary artery ligation [116]. This work demonstrated reduced
fibrotic area and infarct thickness two weeks after injury.
Thus, in summary, results from a number of different groups have independently
shown that cardiac function post infarction can be improved by reprogramming. Indeed,
reprogramming in vivo tends to produce more mature cardiomyocytes than in vitro efforts,
perhaps because the induced cardiomyocytes receive as-yet unidentified signals from their
cellular environment within the tissue [117].
One caveat of these studies is that the mice used tend to be very young. Qian et al.
used mice at 2 months old, while Song et al. used mice of 8–10 weeks. As mice reach sexual
maturity at 6 weeks, these mice are therefore the equivalent of teenagers or young adults,
whereas in man myocardial infarction is generally a disease affecting older people. As
we know the murine heart maintains an intrinsic regenerative capacity in the neonatal
period [55], and that embryonic cells are generally more easily reprogrammed in vitro [92]
it is likely that reprogramming efficiency would be lower in an older heart.
5. Discussion
In this review, we have shown how a detailed understanding of cell fate determination
during cardiovascular embryonic development has been utilised to inform strategies to
reprogramme cardiac fibroblasts in the injured heart. As was found to be the case in
the embryo, there is not a single transcription factor that can flip a switch between two
differentiated cell states but rather acquisition of a cardiomyocyte fate appears to depend
on a synergistic interaction between multiple factors. This network appears to be somewhat
tolerant of substitutions, but there are species-specific differences.
It is perhaps noteworthy that almost a decade after in vivo reprogramming was first
reported in a mouse model of myocardial infarction, there are as yet no published clinical
successes and no current studies are listed in clinicaltrials.gov. This is indicative of the
many challenges that remain to be overcome in the field before this potential can be realised
in the clinic [117,118]. Two key issues remain unsolved. These are the low rate of observed
reprogramming and safety concerns regarding the use of integrating viral vectors.
Determining the level of reprogramming required to obtain a clinically relevant out-
come for patients is a key question. Most studies report a relatively low rate of reprogram-
ming even in the young heart (Table 2), raising concerns that this may be insufficient to
improve cardiac function in elderly patients. Nevertheless, evidence from mouse models
has suggested that a relatively low level of reprogramming can result in a measurable im-
provement in cardiac function. For example, Qian et al. reported a significant improvement
in ejection fraction and stroke volume with a reprogramming rate of 10–15% [98], while
Song et al. found that the stroke volume of treated animals exceeded that of unoperated
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controls at 12 weeks [90]. We do not yet know whether the same effect would be seen
in a patient and some have suggested a much higher level of reprogramming is needed,
perhaps as high as 50% [119]. Only the recently published streamlined method developed
in the Qian lab has approached this level of efficiency, achieving a rate of 40–60% [107,108],
but this is an in vitro method that utilises a selectable marker for infected cells limiting
its potential for translation. Perhaps a fruitful avenue for future basic research would be
to study the relationship between reprogramming efficiency and functional recovery in
the mouse MI model, or a more clinically relevant animal model such as the pig, in order
to put a more precise figure on the required reprogramming threshold to inform future
efforts. We also need more detailed data on the long-term impacts of reprogramming. How
long do reprogrammed cells survive, are they epigenetically compromised in some way?
Furthermore, all such studies to date have studied reprogramming in an acute model of
myocardial infarction, studies on chronic heart failure models are lacking [120].
How can reprogramming efficiency be improved in vivo? In simple terms, this in-
volves ensuring that the full complement of reprogramming factors is delivered to as many
cells as possible and that these cells are receptive to those factors. Reprogramming appears
to be effective only for dividing rather than quiescent cells [53,90,98]. To date, the virus
has been delivered at the same time as the coronary artery is ligated in all in vivo mouse
studies, but it may be that efficiency could be improved by treatment at a later stage when
activated fibroblasts are at the peak of their proliferation, before their transdifferentiation
to the more quiescent myofibroblasts (Section 3.2). It will also be important to target these
cells before harmful collagen deposition occurs. The best timepoint would need to be
optimised. The use of polycistronic vectors improves delivery efficiency and also allows
manipulation of the relative levels of each factor, which also appears to be an important
consideration [88].
Cardiac fibroblasts perform an important role in the heart and therefore we must
ensure that only harmful scar tissue is reprogrammed. How can we target reprogramming
to specific cell populations to prevent harmful off-target effects? Perhaps the answer to this
may lie in engineering vectors to drive expression using enhancers/promoters active only
in activated myofibroblasts, or by building in negative selection, which shuts down the
expression of reprogramming factors if present in an unwanted cell type. Viruses could be
targeted to specific cell types by engineering surface epitopes.
Safety is a concern with any viral vector due to the danger of oncogenic insertional
mutagenesis and this has been an impediment in the clinical application of this technology.
Qian’s highly efficient method [107,108] nevertheless depends on the use of integrating
viruses, which may be unsafe for clinical use, and development of a non-integrating ap-
proach is needed. To this end, results from Ieda’s lab in mice using the non-integrating
Sendai virus are promising, and fortuitously this method also appears to improve repro-
gramming efficiency [113].
An alternative approach to improve safety may be to eliminate the viral vector entirely
and to find alternative methods. Small molecule drugs can modify epigenetic status [109].
Chang et al. have demonstrated the successful delivery of GMT using gold nanoparticles
coated with an arginine-rich peptide in a mouse model of MI [116]. However, these are
non-specific methods that do not specifically target activated myofibroblasts and may result
in harmful alterations to other cells in the heart. In addition, small molecule epigenetic
modifiers may modify off-target gene loci.
A modification of CRISPR gene editing may provide a method to specifically modify
the epigenetic status of endogenous genes required for reprogramming. A modified enzy-
matically inactive version of CAS9, known as dead CAS9 (dCAS9) can be targeted using
short guide RNAs to enhancers of transcription factors such as the GMHT network [114].
The guide RNA contains aptamers that recruit transcriptional activators to the locus, while
CAS9 itself can be engineered to contain an activation domain [121]. This method has the
advantage of activating endogenous genes rather than driving transgene expression and is
also more easily adaptable to target different genes in the cardiogenic network. However,
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expression of dCAS9 in the original protocol required viral transduction and an alternative
non-viral delivery method needs to be developed.
miRNA has been shown to be effective in reprogramming [106]. Although in vivo
work to date has used a viral vector to drive miRNA expression, it is possible to de-
liver miRNA to cells without the use of a virus. For example, miRNAs are known to be
transferred between cells by extracellular vesicles and these can be harnessed as novel
therapeutics [122]. miRNA or synthetic mimics can be loaded into vesicles produced
in vitro and these could in theory be targeted to specific populations of cells within the
injured heart by engineering of transmembrane proteins [123]. Such an approach may also
be useful for delivery of drugs or mRNA.
Despite these hurdles that remain to be fully overcome the field offers much hope
that one day a patient arriving at an intensive cardiac unit following an acute myocardial
infarction may receive a simple injection as part of their treatment and this might serve to
regenerate the myocardium, preventing fibrosis and restoring cardiac function.
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